Esperanza B. Papadopoulos, MD -- Clinical Director, Adult Bone Marrow Transplantation Inpatient Unit

Esperanza B. Papadopoulos, MD

Hematologic Oncologist

Titles

Clinical Director, Adult Bone Marrow Transplantation Inpatient Unit; Associate Vice Chair of Hospital Medicine Inpatient Operations, Department of Medicine

Clinical Expertise

Allogoeneic Hematopoietic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Bone Marrow Failure Syndromes; Cellular Immunotherapy for Treatment of Post-Transplant Infectious Complications and Relapse

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Monday through Friday, 8:00 a.m. to 6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Papadopoulos accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (City of NY retirees only, starting 7/1/23)

Payor Type:
In Network Coverage Type(s): PPO

Blue Cross Blue Shield Federal Employee Program

Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO

Blue Cross Blue Shield New York

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS

Blue Cross Health Plus

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Carrum Health

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

Cigna

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Connecticare

Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO

Emblem

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO

Emblem Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Emblem Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Empire Blue Cross Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO, DSN

Empire Essential

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Fidelis

Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO

Fidelis Managed Medicaid & HARP

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Fidelis Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO

First Health

Payor Type:
In Network Coverage Type(s): PPO

Healthfirst

Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS

Healthfirst Managed Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO

Healthfirst Medicare Advantage

Payor Type:
In Network Coverage Type(s): HMO, PPO

Healthsmart

Payor Type: Commercial
In Network Coverage Type(s): PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

Payor Type: Commercial
In Network Coverage Type(s): HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

Payor Type: Commercial
In Network Coverage Type(s): PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

Payor Type: Commercial
In Network Coverage Type(s): EPO

Horizon Medicare Advantage

Payor Type:
In Network Coverage Type(s): PPO, HMO

Husky CT Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Magnacare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO

Medicare Part A&B (traditional Medicare)

Payor Type:
In Network Coverage Type(s): Federal Government

Multiplan/Beech Street/PHCS

Payor Type: Commercial
In Network Coverage Type(s): Supplemental

MVP

Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP

Non-Participating Plans with Out of Network Benefits

Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

Payor Type:
In Network Coverage Type(s): TBD

Oscar

Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO

Oxford

Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO

Qualcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

Straight NJ Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Straight NY Medicaid

Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government

Tricare

Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO

UMR

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS

United Healthcare

Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO

World Trade Center Health Program (WTC)

Payor Type: Commercial
In Network Coverage Type(s): State Government

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, New York University School of Medicine

Residencies

New York University Medical Center/Bellevue Hospital

Fellowships

New York University Medical Center; Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Hematology; Medical Oncology

I am a board-certified hematologist and oncologist and work as a bone marrow and stem cell transplant physician on the Adult Bone Marrow Transplant Service. I am part of a multidisciplinary team that treats patients using stem cell transplantation to treat a variety of hematologic malignancies. My particular expertise is in the area of allogeneic transplantation — the use of stem cells or bone marrow derived from a donor other than the patient. Stem cells can come from different sources (related or unrelated donors, bone marrow, peripheral blood, or umbilical cord blood units) and be modified in different ways before transplantation. My current focus is risk stratification — determining which type of transplant is best for each patient who is able to undergo and benefit from an allogeneic transplant.

Read more

I am involved in a number of studies designed to find ways to lower the risk of graft-versus-host disease, a serious complication that can follow allogeneic transplantation. In one approach we are developing techniques to separate out the specific cells that evoke this response, the T lymphocytes, and deliver a stem cell product that is very low in these T cells. These approaches are more useful for patients whose acute leukemia or myelodysplastic syndrome is in an early stage of their disease. I am also studying the use of allogeneic stem cell transplants for the treatment of patients with more-advanced leukemia or myelodysplastic syndrome. Along with colleagues here, I am participating in studies of different combination chemotherapy regimens for patients with advanced or refractory acute leukemia. My practice consists of patients with a variety of hematologic malignancies who are in need of an allogeneic transplant, including patients with acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The goal of my practice and clinical research is to be able to offer every patient in need of a transplant the opportunity to undergo this potentially curative therapy.

As Clinical Director of Memorial Sloan Kettering’s adult Bone Marrow Transplantation Inpatient Service, I lead a dedicated team of doctors and nurse specialists who care for patients undergoing transplantation during their stay in the hospital.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Leadership doctors

See all Bone Marrow Transplant Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Publications on PubMed

Visit PubMed for a full listing of Dr. Papadopoulos’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Esperanza B. Papadopoulos discloses the following relationships and financial interests:

  • Aveo
    Ownership / Equity Interests
  • Biogen Idec
    Ownership / Equity Interests
  • Codiak Biosciences, Inc.
    Ownership / Equity Interests
  • Exelixis
    Ownership / Equity Interests
  • Regulus Therapeutics
    Ownership / Equity Interests
  • Yumanity Therapeutics
    Ownership / Equity Interests

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures